Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches

References

• Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., et al. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group", Blood, 84, 1361–1392.
   Google Scholar
• Zackheim, H.S., Amin, S., Kashani-Sabet, M. and McMillan, A. (1999) "Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients", Journal of the American Academy of Dermatology, 40, 418–425.
   PubMed Web of Science ®Google Scholar
• Kim, Y.H., Chow, S., Varghese, A. and Hoppe, RT. (1999) "Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides", Archives of Dermatology, 135, 26— 32.
   PubMedGoogle Scholar
• Sausville, E.A., Eddy, J.L., Makuch, R.W., Fischmann, A.B., Schechter, G.P., Matthews, M., Glatstein, E., et al. (1988) "Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups", Annals of Internal Medicine, 109, 372— 382.
   PubMed Web of Science ®Google Scholar
• Hoppe, R.T., Cox, R.S., Fuks, Z., Price, N.M., Bagshaw, M.A. and Farber, EM. (1979) "Electron-beam therapy for mycosis fungoides: the Stanford University experience", Cancer Treatment Reports, 63, 691 — 700.
   PubMedGoogle Scholar
• Hoppe, R.T., Wood, G.S. and Abel, E.A. (1990) "Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment", Current Problems in Cancer, 14, 293–371.
   PubMed Web of Science ®Google Scholar
• Kim, Y.H. and Hoppe, R.T. (1999) "Mycosis fungoides and the Sézary syndrome", Seminars in Oncology, 26, 276–289.
   PubMed Web of Science ®Google Scholar
• Merlo, C.J., Hoppe, R.T., Abel, E. and Cox, R.S. (1987) "Extracutaneous mycosis fungoides", Cancer, 60, 397 — 402.
   Google Scholar
• van Doom, R., Van Haselen, C.W., van Voorst Vader, P.C., Geerts, ML., Heule, F., de Rie, M., et al. (2000) "Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients", Archives of Dermatology, 136, 504 — 510.
   Google Scholar
• Foss, F.M. (2002) "Cutaneous T-cell lymphoma", Hematology, (Am Soc Hematol Educ Program), 273–282.
   Google Scholar
• Von Hoff, D.D. (1990) "Phase I clinical trials with fludarabine phosphate" Seminars in Oncology, 17, 33–38.
   Google Scholar
• Kaye, F.J., Bunn, P.A. Jr, Steinberg, S.M., Stocker, J.L., Ihde, D.C., Fischmann, A.B., et al. (1989) "A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides", New England Journal of Medicine, 321, 1784— 1790.
   Web of Science ®Google Scholar
• Foss, F.M. (2000) "An oncologist's approach to therapy for cutaneous T-cell lymphoma", Clinical Lymphoma 1 (Suppl. 1), S9— S14.
   PubMedGoogle Scholar
• Akpek, G., Koh, H.K., Bogen, S., O'Hara, C. and Foss, F.M. (1999) "Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma", Cancer, 86, 1368— 1376.
   Google Scholar
• Von Hoff, D.D., Dahlberg, S., Hartstock, R.J. and Eyre, H.J. (1990) "Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study", Journal of the National Cancer Institute, 82, 1353— 1355.
   PubMed Web of Science ®Google Scholar
• Sacchi, S., Russo, D., Avvisati, G., Dastoli, G., Lazzarino, M., Pelicci, PG., et al. (1997) "All-trans retinoic acid in hematological malignancies: an update", Haematologica, 82, 106–121.
   PubMed Web of Science ®Google Scholar
• Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, AG., Myskowski, P., et al., Bexarotene Worldwide Study Group. (2001) "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II— III trial results", Journal of Clinical Oncology, 19, 2456— 2471
   Web of Science ®Google Scholar
• Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., et al. (1998) "CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lym-phomas: a phase II multicenter study", European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lym-phoma. Journal of Clinical Oncology, 16, 3257 — 3263.
   PubMed Web of Science ®Google Scholar
• Pangalis, GA., Dimopoulou, M.N., Angelopoulou, M.K., Tse-kouras, C., Vassilakopoulos, T.P., Vaiopoulos, G. et al. (2001) "Campath-1H (anti-CD52) monoclonal antibody therapy in lym-phoproliferative disorders", Medical Oncology, 18, 99–107.
   PubMed Web of Science ®Google Scholar
• Hagberg, H., Lundin, J., Cavallin-Stahl, E., Cavallin-Stahl, E., Freden, S., Juliusson, G., et al. (2002) "Phase 2 study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides/Sézary syndrome", Annals of Oncology 13 (Suppl. 2): 85 [abstract 291].
   Google Scholar
• Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., et al. (2001) "Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lympho-ma", Journal of Clinical Oncology, 19, 376— 388.
   Google Scholar
• Kreitman, R.J., Wilson, W.H., White, J.D., Stetler-Stevenson, M., Jaffe, ES., Giardina, S., et al. (2000) "Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hema-tologic malignancies", Journal of Clinical Oncology, 18, 1622— 1636.
   PubMed Web of Science ®Google Scholar
• Duvic, M., Martin, AG., Kim, Y., Olsen, E., Wood, G.S., Crowley, CA., et al., Worldwide Bexarotene Study Group. (2001) "Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma", Archives of Dermatology, 137, 581 —593.
   PubMedGoogle Scholar
• Zhang, C., Hazarika, P., Ni, X., Weidner, D.A. and Duvic, M. (2002) "Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action", Clinical Cancer Research, 8, 1234–1240.
   PubMed Web of Science ®Google Scholar
• Talpur, R., Ward, S., Apisarnthanarax, N., Breuer-Mcham, J. and Duvic, M. (2002) "Optimizing bexarotene therapy for cutaneous T-cell lymphoma", Journal of the American Academy of Dermatology, 47, 672–684.
   Google Scholar
• Breneman, D., Duvic, M., Kuzel, T., Yocum, R., Truglia, J. and Stevens, V.J. (2002) "Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma", Archives of Dermatology, 138, 325–332.
   PubMed Web of Science ®Google Scholar
• French, L.E., Shapiro, M., Junkins-Hopkins, J.M., Vittorio, C.C. and Rook, A.H. (2001) "Regression of multifocal, skin-restricted CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy", Journal of the American Academy of Derma-tology, 45, 914 — 918.
   Google Scholar
• Brandhuber, B.J., Boone, T., Kenney, W.C. and McKay, D.B. (1987) "Three-dimensional structure of interleukin-2", Science, 238, 1707 — 1709.
   Web of Science ®Google Scholar
• Saleh, M.N., LeMaistre, CF., Kuzel, TM., Foss, F., Platanias, L.C., Schwartz, G., et al. (1998) "Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides", Journal of the American Academy of Dermatology, 39, 63–73.
   PubMed Web of Science ®Google Scholar
• Re, G.G., Waters, C., Poisson, L., Willingham, MC., Sugamura, K. and Frankel, A.E. (1996) "Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells", Cancer Research, 56, 2590–2595.
   PubMed Web of Science ®Google Scholar
• Gorgun, G. and Foss, F.M. (2002) "Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox", Blood, 100, 1399 — 1403.
   Google Scholar
• Foss, F.M. (2000) "Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: Single-agent and combination studies", Seminars in Oncology, 27, 58–63.
   PubMed Web of Science ®Google Scholar
• Piekarz, R.L., Robey, R., Sandor, V., Bakke, S., Wilson, W.H., Dahmoush, L., et al. (2001) "Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report", Blood, 98, 2865–2868.
   Google Scholar
• Qin, J.Z., Zhang, CL., Kamarashev, J., Dummer, R., Burg, G. and Dobbeling, U. (2001) "Interleukin-7 and interleukin-15 regulate the expression of the bc1-2 and c-myb genes in cutaneous T-cell lymphoma cells", Blood, 98, 2778 — 2783.
   PubMedGoogle Scholar
• Zucker-Franklin, D. (2002) "The role of interleukin-7 and interleukin-15 in cutaneous T-cell lymphoma", Blood, 99, 3488.
   PubMedGoogle Scholar
• Vonderheid, E.C. (2002) "Treatment of cutaneous T-cell lymphoma: 2001", Recent Results in Cancer Research, 160, 309 — 320.
   PubMedGoogle Scholar
• Showe, L.C., Fox, FE., Williams, D., Au, K., Niu, Z. and Rook, A.H. (1999) "Depressed IL-12-mediated signal tansduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor-2 mRNA and highly reduced levels of STAT4", Journal of Immunology, 163, 4073–4079.
   PubMed Web of Science ®Google Scholar
• Rook, A.H., Zaki, M.H., Wysocka, M., Wood, G.S., Duvic, M., Showe, L.C., et al. (2001) "The role for interleukin-12 therapy of cutaneous T cell lymphoma", Annals of the New York Academy of Sciences, 941, 177 — 184.
   PubMed Web of Science ®Google Scholar
• Berger, CL., Hanlon, D., Kanada, D., Dhodapkar, M., Lombillo, V., Wang, N., et al. (2002) "The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells", Blood, 99, 2929–2939.
   Google Scholar
• Bladon, J. and Taylor, P.C. (2002) "Extracorporeal photopheresis in cutaneous T-cell lymphoma and graft- versus-host disease induces both immediate and progressive apoptotic processes", British Journal of Dermatology, 146, 59–68.
   Google Scholar
• Rook, A.H. and Wolfe, JT. (1994) "Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection", Journal of Clinical Apheresis, 9, 28— 30.
   Google Scholar
• Heald, P.W., Perez, MI., McKiernan, G., Christensen, I. and Edelson, R.L. (1990) "Extracorporeal photochemotherapy for CTCL", Progress in Clinical and Biological Research, 337, 443–447.
   PubMedGoogle Scholar
• Knobler, R. and Girardi, M. (2001) "Extracorporeal photoche-moimmunotherapy in cutaneous T cell lymphomas", Annals of the New York Academy of Sciences, 941, 123 — 138.
   PubMed Web of Science ®Google Scholar
• Lim, H.W. and Edelson, R.L. (1995) "Photopheresis for the treatment of cutaneous T-cell lymphoma", Hematology/Oncology Clinics of North America, 9, 1117 — 1126.
   PubMed Web of Science ®Google Scholar